Further increases (to 7.5 mg, 10 mg, and potentially 15 mg) usually occur in 2.5 mg increments, typically only after at least four weeks on the current dose and based on your individual response and tolerance
Orforglipron (Orfoglip), approved in 2025, is the newest oral GLP-1 agonist
However, severe pancreatitis can lead to organ failure or death, which is why prompt care is essential
Conclusion Increasing your dose of Semaglutide or Tirzepatide should be a gradual process thats done carefully and based on your individual progress
The future likely involves both drugs coexisting as options for different patient profiles, similar to how semaglutide and tirzepatide both have their place in current practice
But "tend to" is not a guarantee